Drug intelligence / Profile preview

[11C]DPA-713

Development stage
Phase 1
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[11C]DPA-713 is a radiolabeled small molecule used as a positron emission tomography (PET) imaging agent. It is a selective ligand for the translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor, which is upregulated in activated microglia and other cells during neuroinflammation. By binding to TSPO, [11C]DPA-713 enables noninvasive visualization and quantification of neuroinflammatory processes in vivo. Compared to earlier TSPO PET tracers such as [11C](R)-PK11195, [11C]DPA-713 demonstrates higher specific binding, improved signal-to-noise ratio due to lower nonspecific binding, and greater sensitivity for detecting increased TSPO expression in both preclinical models and human studies. It has been evaluated for use in various neurological conditions associated with neuroinflammation including epilepsy, schizophrenia, bipolar disorder, ischemic stroke models in animals, and Gulf War Illness[1][2][3][4][5][6][7].

Other names
DPA-713DPA713DPA 713N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide
02

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on [11C]DPA-713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]DPA-713.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call